Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Invitae Dropped as Much as 18.3% Today

By Maxx Chatsko - Feb 13, 2018 at 11:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The genetic testing leader announced full-year 2017 earnings.

What happened

Shares of genetic testing and genomics specialist Invitae (NVTA 9.25%) crashed over 18% Tuesday morning after the company announced fourth-quarter and full-year 2017 earnings. Mr. Market sent the stock sharply lower last month when the company provided preliminary expectations to investors. The finalized results published Tuesday were actually slightly better than the preliminary results from last month. Nonetheless, Wall Street punished the stock again in a move that is a bit of a head-scratcher.

There are a few angles to the full-year 2017 results that investors should consider, especially as Wall Street grapples with both high growth and relatively high levels of dilution. As of 11:55 a.m. EST, the stock had settled to a 9.5% loss.

A chart with a negative slope drawn on a chalkboard.

Image source: Getty Images.

So what

Here's a look at Invitae's full-year 2017 operational results compared to the prior-year period:




% Difference

Test volume





$68.2 million

$25 million


Gross profit

$18.1 million

($2.8 million)


Operating income

($121.3 million)

($100.2 million)


Net income

($123.4 million)

($100.3 million)


COGS per sample




Cash burn

$97.7 million

$76.3 million


Source: Invitae.

The company held firm on the preliminary guidance for 2018 provided last month. Invitae still expects to process at least 250,000 tests and generate revenue of at least $120 million in the year ahead. The increase is owed to a combination of growth in the base business, contributions from four acquisitions, and an uptick in biopharma collaboration revenue. Regarding the latter, the genetic testing leader now has partnerships with over 12 biopharma companies.

While the revenue growth is astonishing, Wall Street is still concerned about cash burn and mounting losses. Invitae has largely financed its growth to date with share dilution. Considering the business burned through roughly $98 million in cash last year and entered 2018 with just $76 million in cash and cash equivalents on hand, analysts can already see what's likely coming: more dilution.

Now what

Invitae is now hovering at a market cap of just $300 million. While that seems pretty cheap given the long-term potential, it's important to keep in mind that more dilution will be needed to fund operations and growth for the foreseeable future. The company is a long way from profitable operations or cash flow breakeven, and Wall Street seems to be factoring that into the stock's recent slide.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Invitae Stock Quote
$3.07 (9.25%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.